文献速递糖尿病

1型糖尿病患者中非酒精性脂肪性肝病(NAFLD)的患病率:系统综述与Meta分析

Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该系统综述与Meta分析检索截至2020年3月的PubMed和Embase,纳入2009至2019年间20项研究(n=3901),评估1型糖尿病患者中NAFLD的合并患病率。合并患病率为19.3%(95%CI 12.3%-27.5%),成人中升至22.0%(95%CI 13.9%-31.2%),且患病率高度依赖于诊断方法和NAFLD定义。

要点

  • 1型糖尿病患者NAFLD合并患病率为19.3%(95%CI 12.3%-27.5%),成人中为22.0%(95%CI 13.9%-31.2%)。
  • 超声研究合并患病率27.1%(95%CI 18.7%-36.3%),磁共振成像为8.6%(95%CI 2.1%-18.6%)。
  • 肝活检研究合并患病率19.3%(95%CI 10.0%-30.7%),瞬时弹性成像为2.3%(95%CI 0.6%-4.8%)。

核心结论

  • 1型糖尿病患者中NAFLD患病率相当高,且高度依赖于所用诊断方法和NAFLD定义。
  • 这些数据有助于指导标准化NAFLD诊断的行动,从而帮助明确其 contributing 机制和结局。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed和Embase截至2020年3月,并筛查纳入文献的参考文献。
  • 由两名作者独立筛选标题/摘要,一名作者筛选全文;一名研究者使用标准化表格提取数据并评估偏倚风险。
  • 纳入2009年至2019年间的20项研究,总样本量n=3901。
  • NAFLD定义按各原始研究所述(脂肪变性和/或纤维化);排除未报告肝脂肪变性其他原因或仅将NAFLD定义为肝酶升高的研究。

主要发现

  • NAFLD合并患病率为19.3%(95%CI 12.3%-27.5%),成人中升至22.0%(95%CI 13.9%-31.2%)。
  • 超声研究合并患病率为27.1%(95%CI 18.7%-36.3%),磁共振成像研究为8.6%(95%CI 2.1%-18.6%)。
  • 肝活检研究合并患病率为19.3%(95%CI 10.0%-30.7%),瞬时弹性成像研究为2.3%(95%CI 0.6%-4.8%)。

关键数值与推荐

  • 采用随机效应模型进行Meta分析评估合并患病率,随后通过亚组分析、Meta回归和敏感性分析探索异质性。
  • NAFLD定义为原始研究所述的脂肪变性和/或纤维化;排除仅以肝酶升高定义NAFLD的研究。
  • 最终纳入20项研究(n=3901),来自最初符合筛选标准的919篇文章。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Nonalcoholic fatty liver disease (NAFLD) prevalence is high, especially in patients with obesity and type 2 diabetes, and is expected to rise steeply in the coming decades. OBJECTIVE: We estimated NAFLD prevalence in patients with type 1 diabetes and explored associated characteristics and outcomes. DATA SOURCES: We reviewed PubMed and Embase for studies on NAFLD and type 1 diabetes to March 2020. We screened references of included articles. STUDY SELECTION: Two authors independently screened titles/abstracts. One author screened full text articles. NAFLD was defined as described in the individual studies: steatosis and/or fibrosis. Studies not reporting alternative causes of hepatic steatosis or defining NAFLD only as elevated liver enzymes, were excluded. Initially, 919 articles met the selection criteria. DATA EXTRACTION: One researcher performed data extraction and risk of bias assessment using standardized tables. DATA SYNTHESIS: We assessed pooled prevalence rates by meta-analysis using a random-effects model, subsequently exploring heterogeneity by subgroup-, meta-regression-, and sensitivity analysis. Twenty studies between 2009 and 2019 were included (n = 3901). Pooled NAFLD prevalence was 19.3% (95% CI, 12.3%-27.5%), increasing to 22.0% (95% CI, 13.9%-31.2%) in adults only. Pooled prevalence of ultrasound studies was high (27.1%, 95% CI, 18.7%-36.3%) compared to studies using magnetic resonance imaging (8.6%, 95% CI, 2.1%-18.6%), liver biopsy (19.3%, 95% CI, 10.0%-30.7%), or transient elastography (2.3%, 95% CI, 0.6%-4.8%). CONCLUSION: NAFLD prevalence in patients with type 1 diabetes is considerable and is highly dependent on the specific diagnostic modality and NAFLD definition used. These data are helpful in directing actions to standardize NAFLD diagnosis, which will help defining contributing mechanisms and outcomes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. de Vries M, Westerink J, Kaasjager KHAH, et al. Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020. PMID: 32827432. doi:10.1210/clinem/dgaa575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。